These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Zou H; Zhou B; Xu G Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711 [TBL] [Abstract][Full Text] [Related]
26. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Fernandez-Fernandez B; Fernandez-Prado R; Górriz JL; Martinez-Castelao A; Navarro-González JF; Porrini E; Soler MJ; Ortiz A Clin Kidney J; 2019 Jun; 12(3):313-321. PubMed ID: 31198532 [TBL] [Abstract][Full Text] [Related]
27. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232 [TBL] [Abstract][Full Text] [Related]
28. The kidney and cardiovascular outcome trials. Bloomgarden Z J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006 [TBL] [Abstract][Full Text] [Related]
29. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease? Doggrell SA Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251 [No Abstract] [Full Text] [Related]
31. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management. Beavers CJ Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052 [TBL] [Abstract][Full Text] [Related]
32. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ; Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812 [TBL] [Abstract][Full Text] [Related]
33. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Antlanger M; Domenig O; Kaltenecker CC; Kovarik JJ; Rathkolb V; Müller MM; Schwaiger E; Hecking M; Poglitsch M; Säemann MD; Kopecky C Diabetes Obes Metab; 2022 May; 24(5):816-826. PubMed ID: 34984822 [TBL] [Abstract][Full Text] [Related]
34. Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. D'Marco L; Puchades MJ; Gandía L; Forquet C; Giménez-Civera E; Panizo N; Reque J; Juan-García I; Bermúdez V; Gorriz JL touchREV Endocrinol; 2021 Nov; 17(2):84-87. PubMed ID: 35118452 [TBL] [Abstract][Full Text] [Related]
36. The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. Provenzano M; Jongs N; Vart P; Stefánsson BV; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Toto RD; Wheeler DC; Heerspink HJL; Kidney Int Rep; 2022 Mar; 7(3):436-443. PubMed ID: 35257056 [TBL] [Abstract][Full Text] [Related]
37. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928 [TBL] [Abstract][Full Text] [Related]
38. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. DeFronzo RA; Bakris GL Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284 [TBL] [Abstract][Full Text] [Related]
39. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis. Liu T; Li R; Wang X; Gao X; Zhang X Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768 [TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved. Sarafidis P; Papadopoulos CE; Kamperidis V; Giannakoulas G; Doumas M Hypertension; 2021 May; 77(5):1442-1455. PubMed ID: 33775130 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]